Patents by Inventor George L. Long

George L. Long has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5270040
    Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce subfragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
    Type: Grant
    Filed: July 1, 1992
    Date of Patent: December 14, 1993
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Robert J. Beckmann, S. R. Jaskunas, Mei-Huei T. Lai, Sheila P. Little, George L. Long, Robert F. Santerre
  • Patent number: 5151268
    Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce sub-fragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
    Type: Grant
    Filed: July 5, 1988
    Date of Patent: September 29, 1992
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Robert J. Beckmann, S. Richard Jaskunas, Mei-Huei T. Lai, Sheila P. Little, George L. Long, Robert F. Santerre
  • Patent number: 4775624
    Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce sub-fragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
    Type: Grant
    Filed: February 8, 1985
    Date of Patent: October 4, 1988
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Robert J. Beckmann, S. Richard Jaskunas, Mei-Huei T. Lai, Shelia P. Little, George L. Long, Robert F. Santerre
  • Patent number: 4738921
    Abstract: The present invention comprises improved derivatives of the tryptophan operon useful for expressing fused gene products in E. coli and relate organism. Two of the improved derivatives disclosed are encoded on 0.43 and 0.55 kb EcoRI restriction fragments from plasmids pCZ20 and pLEBGH2 (in strains NRRL B-15881 and NRRL B-15882), respectively. The modified derivatives have been placed on recombinant DNA cloning and expression vectors. A variety of expression vectors have been constructed that drive expression of fused gene products. Two novel gene sequences, encoding insulin-like growth factors I and II, have been expressed with the modified tryptophan operon system.
    Type: Grant
    Filed: September 27, 1984
    Date of Patent: April 19, 1988
    Assignee: Eli Lilly and Company
    Inventors: Ramamoorthy Belagaje, Janet K. Epp, JoAnn Hoskins, Hansen M. Hsiung, George L. Long, Brigitte E. Schoner